Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
Article excerpt
Highlighted: the sentence this signal was extracted from
Sanofi and Regeneron expand global Alliance with multiple nex t-generation, long-acting immunology antibodies Paris and Tarrytown, NY, October 1, 2026. Sanofi and Regeneron Pharmaceuticals, Inc. today announce an expansion of their longstanding antibody collaboration, adding multiple next-generation, long-acting antibodies to the Alliance that has jointly established Dupixent® (dupilumab) as the world-leading treatment for diseases driven by type 2 inflammation. The agreement builds on the companies' more than 20-year collaboration, through which more than 1.5 million people are currently receiving Dupixent across nine indications, making it one of the most widely used antibody medicines in the world. "This is a deliberate first step in igniting Sanofi's innovation engine. Our longstanding Alliance with Regeneron has transformed the treatment landscape for millions of patients living with diseases driven by type 2 inflammation and created one of the world's leading immunology businesses," said Belén Garijo, Chief Executive Officer of Sanofi. "By deepening our collaboration, we will make rapid progress in creating the next generation of meaningful therapies for patients with immune-mediated diseases, while contributing to Sanofi's long-term future." Under the expanded license and collaboration agreement, the companies will co-develop and co-commercialize four new long-acting...
Keep reading with a free account
The rest of this article, and every signal for Sanofi, is in your free account.